Clinical trials
Breast Cancer Patients clinical trials
Below are recruiting breast cancer patients clinical trials, each written for real people, not researchers. We’re tracking 2,205 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03514368Recruiting
Testing immune markers to track cancer treatment safety and benefit
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
ToulouseAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT06875414Recruiting
Breast cancer and couple resilience study
This study looks at how couples handle a breast cancer diagnosis and treatment together. Researchers want to understand how the relationship affects coping and well-being.
Roma, RomeAges 18 years+ - NCT02594202Recruiting
Collecting prostate cancer care details and prostate tissue samples
This trial enrolls adults who are being evaluated or treated for possible or confirmed prostate cancer and allows researchers to collect prostate tissue. It may help improve understanding of prostate cancer over the course of diagnosis and standard care.
Bethesda, MarylandAges 18 years+ - NCT07290894RecruitingPhase 2
Pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
NaplesAges 18 years+ - NCT07723209Recruiting
Radiation after no lymph node sampling in breast cancer
This trial tests whether radiation therapy alone is safe and effective for women 40 and older with early-stage breast cancer who have not had lymph node sampling. It aims to simplify treatment while maintaining good outcomes.
New York, New YorkAges 40 years+ - NCT07669519RecruitingPhase 3
Supplement for fatigue in stage IV colon cancer
This study tests an oral supplement (Nuvastatic) to see if it helps reduce fatigue in people with stage IV colon cancer who are starting chemotherapy for the first time. If you are 18–65 and have fatigue that is affecting you, this trial might offer a way to feel better.
Srikakulam, Andhra PradeshAges 18–65 - NCT06704659Recruiting
Repeated radiation for recurrent breast cancer
This study tests giving a second round of radiation therapy to women whose breast cancer has come back in the same breast, at least 3 years after their first radiation. It may be an option for women 55 and older who have a small, local recurrence that can be removed with surgery.
HelsinkiAges 55 years+ - NCT06958627RecruitingPhase 2/Phase 3
Smart phone app vs standard care for breast cancer treatment
This trial tests whether a smartphone-based patient management program helps women with HER2-positive breast cancer take their medication (pyrotinib) more consistently compared to usual care. It may be a good fit if you are starting or continuing pyrotinib treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06963723Recruiting
Screening for financial hardship in advanced cancer
This study screens people with advanced cancer for financial problems. It aims to see if catching these problems early can improve your care and well-being.
Phoenix, ArizonaAges 21 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT07039552Recruiting
Ovarian cancer risk check for family members
This study looks at family members of people with ovarian cancer to build a better tool for predicting their risk. If you have a BRCA1 or BRCA2 gene mutation, you may be able to join.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05416164Recruiting
Testes less radiation after a complete response to medicines
This study checks whether some people with breast cancer who have no remaining cancer after medicine (neoadjuvant systemic therapy) can safely receive less radiation. It may help reduce side effects while still keeping cancer controlled.
Amsterdam, North HollandAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT07124546Recruiting
Acceptance and commitment therapy for cancer distress
This trial tests a type of counseling called acceptance and commitment therapy (ACT) to help people with incurable cancer feel less distressed. It is done in a group over the internet, so you can join from home.
Rochester, MinnesotaAges 18 years+ - NCT05913999Enrolling by invitation
PET and heart scans during early chemotherapy
This trial studies how a specialized heart imaging test (PET/MPI) changes during the start of chemotherapy for cancer patients. It may help researchers understand whether this monitoring approach detects heart strain early and keeps patients safer during treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07064018RecruitingPhase 1/Phase 2
SPEDOX-6 for advanced solid tumors
This trial tests a new form of the chemotherapy drug doxorubicin, called SPEDOX-6, for people with certain advanced solid tumors that haven't responded to at least two prior treatments. The drug is designed to deliver doxorubicin directly to cancer cells while possibly reducing side effects.
Orange, CaliforniaAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
Duarte, CaliforniaAges 18 years+ - NCT06439771RecruitingPhase 2
Testing YL202 for advanced breast cancer
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04601116RecruitingPhase 3
Atorvastatin for hormone-positive breast cancer to prevent recurrence
This Phase 3 study tests whether taking atorvastatin (a cholesterol-lowering medicine) can improve outcomes for women with estrogen-receptor–positive breast cancer. It may help by affecting cancer-related pathways and reducing risk of recurrence or progression.
AarhusAges 18 years+ - NCT07779135Recruiting
Aromatherapy for nerve pain from breast cancer treatment
This study tests whether using essential oils can help reduce pain, tingling, or numbness in hands and feet caused by paclitaxel chemotherapy for breast cancer. If regular pain medications aren't working well, this natural approach may offer additional relief.
ColmarAges 18 years+ - NCT07407439Recruiting
Real-world study of CDK4/6 inhibitors in advanced breast cancer
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
TianjinAges 18 years+
Hear when a new Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer patients?
- Yes. Clin2 currently lists 2,205 recruiting breast cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.